Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis

Company Overview

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key Stats

• Today's Range: $1.91 to $2.02
• 50-Day Range: $1.60 to $2.05
• 52-Week Range: $1.39 to $3.81
• Volume: 242,266 shs
• Average Volume: 115,090 shs
• Market Capitalization: $93.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Whitehawk Therapeutics Stock Analysis - MarketRank™

Whitehawk Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Whitehawk Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Whitehawk Therapeutics is -33.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Whitehawk Therapeutics is -33.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Whitehawk Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.93% of the float of Whitehawk Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Whitehawk Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Whitehawk Therapeutics does not currently pay a dividend.

Dividend Growth

Whitehawk Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.93% of the float of Whitehawk Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Whitehawk Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Whitehawk Therapeutics has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.21 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Whitehawk Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Whitehawk Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

49.90% of the stock of Whitehawk Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.08% of the stock of Whitehawk Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WHWK Stock Analysis - Frequently Asked Questions

How have WHWK shares performed this year?

Whitehawk Therapeutics' stock was trading at $1.87 at the start of the year. Since then, WHWK shares have increased by 6.4% and is now trading at $1.99.

How were Whitehawk Therapeutics' earnings last quarter?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) released its earnings results on Thursday, August, 7th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of $0.49 by $1.25. Whitehawk Therapeutics had a net margin of 99.42% and a negative trailing twelve-month return on equity of 75.99%.

How do I buy shares of Whitehawk Therapeutics?

Shares of WHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WHWK
• CIK: 1422142
• Web: N/A
• Phone: (424) 473-8055
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.69 million
• Net Margins: 99.42%
• Pretax Margin: -48.24%
• Return on Equity: -75.99%
• Return on Assets: -68.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.41
• Quick Ratio: 20.41

Sales & Book Value

• Annual Sales: $25.98 million
• Price / Sales: 3.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.12 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 47,130,000
• Free Float: 23,611,000
• Market Cap: $93.79 million
• Optionable: N/A
• Beta: 0.51